NEW YORK (GenomeWeb) – Nanostring Technologies today announced that its Prosigna Breast Cancer Assay has been acknowledged within the treatment guidelines of the German Association of Gynecological Oncology (AGO).

The company also said that a recent decision by the German Joint Federal Committee (G-BA) has qualified German breast cancer patients with statutory government insurance as eligible for coverage for gene expression testing, such as that provided by Prosigna, to inform therapy decisions beginning April 1.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.